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Abstract:
Huntington’s disease (HD) is an incurable genetic neurological disorder that affects 1 in
10,000 people, with no treatment that can alter the course of the disease. Neural cell death
in the striatum and the cortex results from the accumulation of toxic mutant huntingtin
protein (mHTT) fragments. Full length HTT is cleaved by proteases, including caspases,
calpains and matrix metalloproteinases (MMPs). Previous research has also shown
altered kinase signaling pathways in HD contribute to the localization of mutant
huntingtin to the nucleus and to disruption of transcriptional regulation. Currently, there
are no drugs that delay the onset or slow the progression of Huntington’s disease. We
hypothesized that known drugs that target specific enzymes that have been evaluated in
cancers and other neurological diseases may have therapeutic benefit in HD. Such
enzymes that have been evaluated are MMP inhibitors and PCK activators, both enzymes
that have been known to impact proteolytic processing and localization of mutant
huntingtin. We evaluated these previously established compounds and their effect in HD
mouse striatal cells, human neural stem cells, and transgenic mouse models. We have
evaluated three MMP inhibitor compounds and found one that crosses the blood brain
barrier and as predicted inhibits gelatinases. We have also found the PKC activator,
Bryostain-1, increased the average life span in HD R6/2 treated mice.

vi

Specific Aims:
Aim 1: Prior evaluation of MMP in HD cellular models and transgenic mouse models
have shown dysregulated MMP expression and activity in diseased compared to control
samples. MMP dysregulation has also been demonstrated in post-mortem HD patient
tissue as well as cerebrospinal fluid samples of HD patients. The first aim is to
investigate the expression of MMP members, MMP-3/10, MMP-14, MMP-2, MMP-9, and
their localization in patient-derived HD neural stem cells (HD-NSC) and compare
against the CAG-corrected NSC line (C116-NSC). The dysregulation of MMP expression
in human HD neural stem will be studied using immunoblotting techniques and RT- PCR.
Aim 2: Pharmacological inhibitors of MMP (9j, 19v, and 19w) will be utilized to study
the substrate-specific inhibition of MMP class members, gelatinases, to evaluate the
biochemical changes in the brain of C57/BL6 mice. Penetration of 9j, 19w, and 19v
across the blood-brain barrier (BBB) from blood to brain tissue will be evaluated by
LC/MS in conjunction with a pharmacokinetic study. Biochemical changes will be
evaluated via gelatin zymography and MMP enzymatic assays using fluorogenic
substrate.
Aim 3: PKC activation has been shown to offer potential therapeutic benefit in
neurodegenerative diseases, including Alzheimer’s Disease and Multiple Sclerosis.
Bryostain-1, a PKC activator, will be evaluated to determine any beneficial
improvements in locomotor deficits and other behavioral phenotypes in HD R6/2
transgenic mouse model. This will be evaluated using rotarod, open field behavioral
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assays and hind limb clasping assay to monitor locomotor phenotype associated with
disease progression.
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Chapter 1
Abstract:
Huntington’s disease (HD) is an incurable genetic neurological disorder that affects 1 in
10,000 people, with no treatment that can alter the course of the disease. Neuronal cell
death in the striatum and the cortex results from the accumulation of toxic mutant
huntingtin protein (mHTT) fragments. Full-length HTT is cleaved by proteases, including
caspases, calpains and matrix metalloproteinases (MMP). A multitude of MMP inhibitors
have been examined as therapeutic drugs in many diseases including cancer, arthritis, and
cardiovascular disease. However, the effects of MMP inhibition in neurodegenerative
disorders have not been extensively evaluated. We hypothesize a dysregulation of MMPs
and their regulators, tissue inhibitors of matrix metalloproteinases (TIMPs), in the
striatum and cortex contribute to the disease pathology of HD, induced by toxic mutant
huntingtin fragment formation due to proteolytic cleavage. Thus, investigating the role of
MMP inhibition may be a viable route for a HD therapy. Pervious research has shown
increased levels of MMPs in both human HD post mortem tissue and mouse models,
however MMP levels were not studied a HD patient-derived stem cell model. We
evaluated MMP expression levels in our HD-patient derived neural stem cell lines by
immunocytochemistry and western blot analysis. We found decreased expression levels
of MMP-3/10, MMP-14, TIMP-1, and TIMP-2 in our patient derived neural stem cells as
well as altered MMP-2 and MMP-9 activity in cells and in secreted media.
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Immunocytochemistry further provided evidence of MMP and mutant HTT involvement
in HD neural stem cells (NSCs) compared to control corrected NSCs. Further, we
evaluated three MMP inhibitor compounds in HD mouse striatal cell line and found these
compounds were neuroprotective. To determine if these compounds crossed the BBB and
had good pharmacokinetics (PK), we evaluated these compounds in C57BL/6 mice using
LC/MS. One MMP inhibitor compound, 9j, showed modest blood brain barrier
penetration and specific inhibition of gelatinases (MMP-2 and MMP-9). Overall, our
study provided evidence of MMP inhibition is a neuroprotective in mouse striatal cells
and one MMP inhibitor compound (9j) crossed the BBB in C57BL/6 mice. However,
additional behavioral and biochemical evaluation of 9j needs to be conducted in HD
mouse models to provide a better assessment of the beneficial effects of MMP inhibition
in HD in vivo.

Introduction:
HD is an autosomal dominant neurodegenerative disorder that consumes the later
years of life of disease individuals with a triad of symptoms deterring motor ability,
cognition, and psychiatric disturbances. These characteristic symptoms of HD are caused
by progressive neuronal atrophy and cell death in the cortex and striatum of HD patients,
with the GABAergic medium spiny striatal neurons being specifically affected (Huang,
Chen, & Zhang, 2016). Current drug treatments merely offer symptomatic benefit for
movement disorders and psychiatric and behavioral impairments rather than a cure for the
disease. HD pathology arises from polyglutamine (CAG) expansion in the huntingtin
(HTT) gene which is located on chromosome 4 (Huang et al., 2016; Miller et al., 2010).
2

Previous research has shown that intracellular HD pathogenesis arises from abnormal
aggregation of mutant huntingtin (mHTT) protein, impairments in protein clearance,
generation of toxic N-terminal fragments of cleaved truncated mHTT protein, and
impaired cellular metabolic pathways (Ross & Tabrizi, 2011). Additional research has
shown caspase cleavage of mutant N-terminal HTT to be one driver of neurodegenerative
progression in HD (Gafni et al., 2004; Leyva et al., 2010; Schilling et al., 2006a;
Wellington et al., 2002c). Differently sized fragments of expressed mHTT found in the
striatum suggests progression of disease may be caused by proteolysis of mHTT into
fragments cleaved fragments of mHTT (Gafni et al., 2012; Mende-Mueller, Toneff,
Hwang, Chesselet, & Hook, 2001; O'Brien et al., 2015; Wellington et al., 2000;
Wellington et al., 2002a). Of the various proteases involved in cleaving mHTT, caspases
and calpains are most widely studied, however other proteases also have been shown to
cleave mHTT, including MMP-10 (Gafni & Ellerby, 2002; Gafni et al., 2012; Hermel et
al., 2004). An unbiased siRNA-western blot screen of 514 known human proteases
identified 11 proteases that reduced N-terminal toxic fragment formation, three of which
belonged to the matrix metalloproteinases (MMP) family, namely, MMP-10, MMP-14,
and MMP-23B (Miller et al., 2010). Amino acid deletion experiments were conducted to
determine the cleavage of mHtt by MMP-10 to reside at amino acid 402. Proteolysis of
mHTT by MMP-10 increases the mutant N-terminal HTT fragments that in turn would
cause cytotoxicity. Pharmacological or siRNA knockdown MMP family members
decreased cellular toxicity measured by caspase-3/7 activity (Miller et al., 2010).
Inhibiting mHTT proteolysis reduced neuronal toxicity suggesting a causal role between
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mHTT proteolysis and HD pathogenesis. Our goal was to further investigate the role of
MMP inhibition as a potential therapy for HD.
Matrix metalloproteinases are zinc-dependent Ca2+ containing endopeptidases that
are initially synthesized as zymogens and can be activated by other enzymes or free
radicals via a cystine switch. At least 25 human MMP family members have been
discovered so far, and they are categorized based on domain structure and substrate
specificity (Table 1) (Stefano & Herrero, 2016). MMPs are regulated by other MMP
family member as well as their endogenous regulators, tissue inhibitors of matrix
metalloproteinases (TIMPs). TIMPs inhibit MMPs by chelating the catalytic Zn2+ ion in
the MMP catalytic domain. Both MMPs and TIMPs play important roles in several
physiological processes, including extracellular matrix remodeling, wound repair,
angiogenesis, cell migration, and cell differentiation (Loffek, Schilling, & Franzke,
2011).
Dysregulation of MMPs has been widely implicated in the pathogenesis of several
diseases, including cancer, arthritis, and cardiovascular diseases. Recent studies have also
shown their involvement in pathogenesis in central nervous system injury and disease
(Brkic, Balusu, Libert, & Vandenbroucke, 2015). Dysregulation of MMPs has been
linked to various diseases; for example, MMP-3, MMP-1, and MMP-9 upregulation has
been linked to rheumatoid arthritis (Araki & Mimura, 2017). Increased MMP-9 CSF
levels have been reported in late-stage HD patients and HD transgenic mice (Chang, Wu,
Chen, & Chen, 2015; Uchida et al., 2016). Recent literature has also shown that
pharmacological inhibition of MMP-9 correlates with reduced neuronal damage and
decreased neuronal apoptosis (Hadass et al., 2013). Administration of TIMP-2 has shown
4

to increase hippocampal function in aged mice (Castellano et al., 2017). The above
studies underscore the role of MMPs in maintaining cellular homeostasis, demonstrating
that MMP dysregulation can lead to disease pathology.
Because MMP dysfunction is correlated to disease, many therapeutics have been
formulated for MMP inhibition (Vandenbroucke & Libert, 2014a). A plethora of MMP
inhibitors (MMPi) have been assessed in clinical trials for cancer, arthritis, and
cardiovascular disease. Many inhibitors passed phase II and III trials but eventually failed
due to drug-induced toxicity as they are broad-spectrum targets of MMPs. MMP genes
are highly conserved and essential for cells as they have important regulatory functions in
cellular processes such as cell differentiation, migration, survival, apoptosis, growth
factor activation, angiogenesis and inflammation (Vandenbroucke & Libert, 2014a).
Thus, inhibiting broad range MMPs can cause severe complications. For instance, MMP1 and MMP-14 inhibition is associated with musculoskeletal disorders.
Due to severe complications and side effects of broad-range MMP inhibitors,
chemists have synthesized compounds that is less specific at inhibiting the side-effect
causing family members MMP-1 and MMP-14 and specific against a subclass of MMP
family members. Thus, Becker et al. have synthesized MMP-1 and MMP-14-sparing
hydroxamate-based inhibitor compounds (9j, 19v, and 19w) that specifically inhibit
MMP-2, -9, and -13 via allosteric inhibition (irreversible). Synthesized compounds (9j,
19v and 19w) were all potent inhibitors that showed efficient inhibition of tumor growth
in mice and left-ventricular hypertrophy in rats (Becker et al., 2010). Although these
MMP inhibitors have been evaluated in peripheral diseases, the effects of these
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compounds have not been evaluated in the context of neurodegenerative diseases and
have not been evaluated for BBB penetrance.
Increase in MMP levels have been documented in HD mouse models, postmortem human brains of HD cells and patients. To better understand how MMPs
contribute to HD progression in patients, our lab characterized MMP and TIMP
expression in our HD patient (iPSC)-derived HD-NSC line and the CAG-corrected C116NSC line (An et al., 2012). Our results showed altered expression and localization in
MMP-3/10, MMP-14, and activation of MMP-2 and MMP-9 in HD-NSCs compared to
corrected C116-NSCs.
We investigated the effects of cellular toxicity in HD mouse striatal cell line
Hdh111Q/111Q (disease) and Hdh7Q/7Q (control) treated with MMP inhibitors (9j, 19v, 19w).
Rescue of cellular toxicity seen in mouse striatal cells with these MMP inhibitors led us
to investigate the efficacy of these compounds in mice (C57BL/6). We evaluated the
amount of the MMP inhibitors (9j, 19v, 19w) that penetrated the BBB by performing
pharmacokinetic (PK) studies using LC/MS analysis by comparing levels of MMP
inhibitors (9j, 19v, 19w) in the brain relative to plasma levels. Lastly, we evaluated the
specificity of MMP inhibition utilizing gelatin zymography and enzymatic assays using a
fluorogenic substrate (Mac-Pro-Leu-Ala-Nva-Dap (Dnp)-Ala-Arg-NH2). With the
observed changes in MMP and TIMP expression via immunoblotting techniques along
with low levels of cytotoxicity seen by caspase-3/7 assay in HD mouse striatal cell line,
we extended our investigation/evaluation of MMP inhibitors (9j, 19v, 19w) in mice
(C57BL/6). Even with modest amount of compound detected in the brain we did see
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specific inhibition of gelatinases in brain lysates via gelatin zymography and enzymatic
assay analysis.

Methods:
Cell Culture
To generate C116-iPSC and HD-iPSC lines we used STEMdiff Neural Induction Medium
using the protocol from (Ring et al., 2015) and characterized these cells as previously done
in lab (An et al., 2012). Matrigel was used to coat 60 mm dishes for one hour before cells
were plated and cultured in Neural Proliferation Medium (NPM) in a humidified incubator
under 37°C, 5% CO2. Neurobasal medium with 1X B-27 supplement (2mM L-Glutamine,
100U/mL penicillin, 100 μg/mL streptomycin, 10 ng/mL human Leukemia Inhibitory
Factor (LIF) (Peprotech, 300-05), and 25 ng/mL human basic Fibroblast Growth Factor
(bFGF) (Peprotech, 100-18B) was used to prepare the NPM.
Western Blot Analysis
Neural stem cells were lysed with lysis buffer (M-PER + Roche complete protease
inhibitor). Lysates were sonicated for 5 x 5 second pulses at 40 mA. Samples then were
centrifuged at 14,000 rpm at 4ºC and the supernatant collected for western blot analysis.
Protein concentration was measured using a BCA assay (Pierce). 10 – 20µg of total
protein lysate was added to 4X LDS sample buffer (Invitrogen) and 1µl of 1M DTT and
then boiled for 10 minutes at 95°C. SDS-PAGE was performed using a 4% – 12%
NuPAge Bis-Tris gel (Invitrogen). Gels were run at 200V for 55 minutes in MES
(Invitrogen) running buffer, then transferred to PVDF membrane in 1X NuPage transfer
buffer overnight at 20V at 4°C. Membranes were then blocked in TBS with 0.1% Tween
7

20 (TBS-T) and 5 % non-fat milk for one hour. Primary antibodies were reconstituted in
5% non-fat milk in 1X TBS-T and then probed overnight at 4ºC, followed by incubation
with secondary antibody for 3 hours at room temperature. Lastly the membranes were
washed (3X) for 10 minutes, developed using Pierce ECL (Thermo Scientific), and band
intensity was quantified by ImageQuant. α-tubulin and β-actin were used as controls.
Basal levels of MMP and TIMP expression were measured in HD-NSCs and C116NSCs. MMP levels were measured post administration of MMP inhibitor compounds.
Concentrations of primary antibodies used were: MMP-9 (1:100), MMP-2 (1:100),
MMP-3/10 (1:250), TIMP-1 and TIMP-2 (1:250).
Immunocytochemistry
Cells were cultured in 8-well chamber slides (BD Falcon) and fixed in 4%
paraformaldehyde in PBS for 15 minutes at room temperature. Cells were washed 2X
with PBS and blocked for 30 minutes at room temperature with blocking buffer (0.1%
TritonX-100, 5% Donkey Serum, PBS), and then incubated with primary antibody
(suspended in 5% donkey serum in 1% BSA in 1X PBS) at 4ºC overnight. The following
day, slides were washed 3X for 10 minutes and blocked with secondary fluorescently
conjugated antibody (1:200 suspended in 1% BSA in PBS) for 1.5 hours at room
temperature. Slides were washed 3x for 10 minutes with PBS. Lastly, a coverslip was
mounted with ProLong Gold with DAPI (1:500 suspended in PBS) and cured for 24
hours at room temperature. Primary antibodies used were: MMP-14 (1:50), MMP-2
(1:50), MMP-9 (1:50), MMP-3 (1:50), MMP-10 (1:50). Imaging was performed on the
Nikon Eclipse Ti-U microscope.
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Caspase-3/7 Assay
The caspase activity assay was performed with Apo3 HTS kit (Cell Technology).
Hdh111Q/111Q and Hdh7Q/7Q mouse striatal cells were cultured in collagen I coated 96-well
plates (BD) in serum free media (1X DMEM) along with MMP inhibitor compound (9j,
19v, and 19w) for 24 hours. Medium was removed and 50 l of caspase assay lysis buffer
(50% Apo3 HTS lysis buffer/50% PBS) was added into each well. After shaking on an
orbital shaker at 700 rpm for 5 minutes, two 10 l aliquots of lysate were transferred to
new 96 well plates for protein quantification by BCA protein assay (Thermo Scientific).
To the remaining 30µl of cell lysate, 70 l of substrate mix (1X Apo3 HTS Caspase-3/7
detection reagent) and 1 M DTT were added to each well. The plate was shaken at 700
rpm for 30 seconds before reading. The Victor3X spectrophotometer (Perkin Elmer) was
used for this fluorescence-based assay (Ex: 485nm, Em: 530nm) at 37°C. The caspase
activity was normalized against protein concentration of each sample.
Pharmacokinetic Mouse Study
A single dose of 25 mg/kg body weight of MMP inhibitor: 9j (10% EtOH), 19v (10%
EtoH), and 19 (10% EtOH) was injected into the intraperitoneal cavity of the 5-6-weekold C57BL/6 mice (Jackson labs). Twenty one female mice were used for each inhibitor
compound tested (n = 3 for 0.5, 1, 2, 4, 8 hours.). At each subsequent time point, 200 l
of blood was collected from a retro-orbital bleed under controlled isoflurane anesthesia.
Blood was immediately transferred to heparinized tubes (BD) on ice, tubes were spun at
8500 rpm at 4°C for 10 minutes, and plasma was separated into separate tubes for LCMS analysis. Following blood collection, the mouse was sacrificed, the brain was
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harvested, and split into right and left hemispheres, and weights of the individual
hemispheres were recorded. One hemisphere was sent for LC/MS analysis (Integrated
Analytical Solutions Inc.), and the other half was used for gelatin zymography and
enzymatic assay analysis. Analysis of the compounds in plasma and brain at each time
point was conducted by Integrated Analytical Solutions, Inc.
Gelatin Zymography
The right halves of the compound administered mouse brains at each time point were
homogenized with lysis buffer (50mM Tris-HCL,150mM NaCl, 5mM CaCl2, 0.05% Brij35, 1% Triton X-100, 0.02% NaN3), sonicated 3x for 30 seconds, left for 30 seconds of
rest at 40% amplitude and centrifuged at 14,000 rpm for 20 minutes at 4ºC. For HDNSCs and C116-NSCs, cells were homogenized in the same lysis buffer and sonicated for
5 x 5 seconds at 40% amplitude. Following protein determination via BCA assay
(Pierce), tissue (500 µg) and cell (50 µg) whole lysate was incubated with 50 µg of
gelatin Sepharose 4B beads (GE healthcare) on a rotator at 4°C for one hour for MMP
binding. The suspension was centrifuged, the supernatant discarded, and affinity-bound
MMP was eluted with 50 µl of 10% DMSO on a rotator at 4°C for one hour. Affinitypurified MMPs in 1 x LDS dye were then loaded onto 1% gelatin infused 10% SDSPAGE at 90V for 15 minutes, then increased to 150V for 90 minutes. Afterwards, gels
were incubated with 2% Triton X-100 in water for 30 minutes at room temperature,
washed 3X with ddH2O, and incubated in developing buffer (50mM Tris, 5mM CaCl2,
200mM NaCl2, 0.02% Brij-35) for 72 hours at 37°C. Following 72 hour incubation, gels
were stained with 0.5% Coomassie blue (10% acetic acid, 50% methanol) for one hour
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and destained (40% methanol, 10% Acetic acid, 50% ddH2O) for another hour at room
temperature. Lastly, EPSON image scan was used to scan the gels.
Enzymatic Assay
Brain tissues of mice obtained at each timepoint were homogenized in lysis buffer (50
mM Tris-HCL, 150 mM NaCl, 5 mM CaCl2, 0.05% Brij-35, 1% TritonX-100, 0.02%
NaN3), sonicated 3X for 30 seconds with 30 seconds of rest at 40% amplitude and
centrifuged at 14,000 rpm for 20 minutes at 4°C. BCA assay (Pierce) was performed to
determine the protein concentration. 140 µg of protein, 7.5 µM of NNGH, 4µM of
fluorogenic substrate, Mac-Pro-Leu-Ala-Nva-Dap (Dnp)-Ala-Arg-NH2 (Enzo labs), and
assay buffer (50mM HEPES, 10mM CaCl2, 0.05 % Brij-35, pH 7.5) was loaded onto a 96
well black-bottom plate. Substrate fluorescence intensity was measured (Ex: 485nm, Em:
530nm) at 37C by VictorX3 (Perkin Elmer). The enzymatic activity was normalized to
protein concentration of each sample. Fluorescence readings were provided by Workout
Plus software. Fluorescent readings of the drug-induced lysates were compared to the
addition of NNGH, a broad spectrum MMP inhibitor, to measure the overall activity of
MMP-2 and MMP-9.

Results:
Altered MMP-3/10 and MMP-14 Expression in HD-NSCs vs. C116-NSCs
Previous studies have shown dysregulated levels of MMP-14 and cleaved MMP10 in the Hdh111Q/111Q HD mouse striatal line, compared to the Hdh7Q/7Q control line
(Miller et al., 2010). Thus, we looked at the corrected C116-NSC line via
immunocytochemistry and western blot analysis. We found a 1.6-fold increase in MMP11

3/10 expression between the HD-NSCs and the C116-NSCs (Fig. 1A). Antibody staining
shows an altered localization of MMP-3/10; it is cytosolic in C116-NSCs and has an
increased nuclear localization in HD-NSCs. High expression of MMP-3/10 is observed in
degenerated nuclei of apoptotic cells identified by merging DAPI staining and amplified
fluorescent signaling of MMP-3/10 (white arrows) (Fig. 1B). MMP-14 expression levels
were decreased by 1.7 fold in HD-NSCs compared to C116-NSCs as shown by western
blot analysis, (Fig. 2A). Both MMP-14 and HTT antibody staining show nuclear
localization in HD-NSCs compared to C116-NSCs (Fig. 2B).
Gelatinase (MMP-2 and MMP-9) Expression and Activity in NSCs
Dysregulation of MMP-2 and MMP-9 have been implicated in the progression of
various disease pathologies. Increase in neuroinflammatory markers, one of which is
MMP-9, have been observed in HD patients and HD mouse models (Chang et al., 2015).
We looked at the expression, cellular localization, and activity to measure whether these
characteristics are displayed in our HD-patient derived NSCs. Activity of MMP-2 and
MMP-9 were determined using gelatin zymography in whole cell lysates of HD-NSCs as
well as the secreted gelatinase activity in the conditioned media (Fig. 3A and B). We
visually observed a decrease in MMP-2 activity and an increase in the proform of MMP9 in whole cells as well as in the secreted media. Immunocytochemistry further
demonstrates MMP-2 expression is increased in C116-NSCs compared to HD-NSCs
(Fig. 3C). We also observed that MMP-2 expression aligned with apoptotic cells in both
C116-NSCs as well as HD-NSCs (Fig. 3C). We also observed increased nuclear
expression of gelatinases in HD-NSCs (Fig. 3C-D).
Altered TIMP Expression in HD-NSCs and C116-NSCs
12

Tissue inhibitors of Matrix Metalloproteinases (TIMPs) are endogenous inhibitors
of MMPs and previous research has shown elevated TIMP levels in the cerebrospinal
fluid in post-mortem brains of patients with neurodegenerative diseases, such as
Alzheimer’s Disease (AD), Parkinson’s Disease (PD), ALS, and HD (Lorenzl et al.,
2003). We evaluated whether the levels of TIMPs were modulated in our NSCs. We
found that TIMP-1[Fig. 4A (3.3-fold decrease)] and TIMP-2 [Fig. 4B (1.6-fold
decrease)] expression was downregulated in HD-NSCs compared to the CAG corrected
C116-NSC line. We confirmed by immunocytochemistry that the expression of TIMP-1
is decreased in HD-NSCs while the expression levels of HTT aggregates are increased
when compared to C116-NSCs (Fig. 4C).
MMP Inhibitors Reduce Cellular Toxicity in HD Mouse Striatal Cell Line.
We measured, in vitro, the cellular toxicity in HD mouse striatal cells in response to the
treatment of MMP inhibitor compounds (9j, 19v, and 19w). Our experiment measured
caspase-3/7 activity in stressed serum deprived striatal cells with (Hdh111Q/111Q) and
without (Hdh7Q/7Q) CAG expansion. No significant change in the levels of caspase-3/7
activity was detected in the control striatal cell line (Hdh7Q/7Q) between the treated and
non-treated cells. However, we did see a significant reduction in caspase-3/7 activity in
the HD striatal cell line (Hdh111Q/111Q) with 10µM treatment of MMP inhibitor compound.
All three compounds showed a reduction in caspase-3/7 activity between the treated and
non-treated Hdh111Q/11Q cells: 9j, 25% reduction in caspase-3/7 activity (Fig. 5A); with a
p < 0.001, 19v, 30% reduction (Fig. 5B); with a p < 0.001, and 19w, 37% reduction (Fig.
5C); with p < 0.01.
Pharmacokinetic Study of MMP Inhibitor Compounds in Mice
13

MMP inhibitors have been investigated as therapeutic drugs for many peripheral diseases.
Most have failed Phase 1 clinical trials due to complication of broad-spectrum MMP
inhibition. We tested three MMP inhibitor compounds (Table 2) that were synthesized by
Becker et.al group to have MMP-1 sparing ability as well as high specificity of inhibition
towards gelatinases, MMP-2 and MMP-9 (Becker et al., 2010). Initial pharmacokinetic
study was performed using C57/BL6 mice to evaluate the compound that best penetrated
the BBB. Mice were given a single IP injection of 25mg/kg body weight of MMP
inhibitor compound (9j, 19v, and/or 19w), sacrificed at 0.5, 1, 2, 4, and 8 hours postdosing (n = 3 mice per time point) and the brain and plasma levels were analyzed by
LC/MS-MS: 9j compound (Fig. 6A), 19v compound (Fig. 6B), and 19w (Fig. 6C). MMP
inhibitor compounds were detected at an average of 5 µg/ml for 9j, 12 µg/ml for 19v, and
36 µg/ml for 19w in blood plasma at 30 minutes post initial administration. A comparison
of the MMP inhibitor compounds in brain tissue relative to amounts detected in plasma
showed an increase in >5% in all compound, except for 9j (Fig. 6D), however no
statistical significance was found. We calculated the brain tissue to plasma ratio of each
compound at each time point. Percentage of the compound that penetrated the brain from
total amount in plasma was compared at each timepoint for the 9j, 19v, and 19w
administered mice. No statistical significance was found in compound retained in brain
tissue relative to amounts in the plasma at any point post administration. There was also
no significance of the compound retention percentage in brain tissue when compared
between each of the MMP inhibitors except at the eight-hour time point. We observed a
20% increase of the 9j compound in brain tissue was detected in comparison 19v and
19w retention levels (2-way ANOVA, Tukey’s multiple test, p < 0.001) (Fig. 6D). MMP
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inhibitor compound 9j seems to be the best inhibitor compound, of those tested, in
penetrating the BBB as measurement of the ratio comparing the relative amount of
compound in brain tissue to the levels in blood plasma.
Gelatinase (MMP-2 and MMP-9) Inhibition in Brain Tissue Lysates of MMP
Inhibitor Compound Administered Mice
We saw modest amounts of MMP inhibitor compound retention in the brain tissue of
mice, but 9j was seen to have better tissue retention compared to the other two
compounds. Thus, as a further step, we wanted to confirm the specificity of gelatinase
inhibition in 9j administered mice at each time point. To this end we conducted gelatin
zymography to visualize and detect active MMP-2 and MMP-9 in the brain lysates of
MMP inhibitor treated mice. Gelatin zymogram of 9j compound brain lysates (n = 3
mice) shows greater MMP-9 and MMP-2 activity, measured by gelatin degradation, at 30
minutes compared to low to no activity of MMP-9 and MMP-2 at the 4 hour timepoint
post-administration (Fig. 7A). MMP-2 and MMP-9 activity is also reduced at 1 hour and
2 hour post-injection (Fig. 9). Furthermore, quantification of MMP-2 activity of brain
lysates measured by enzymatic assay using a fluorogenic substrate shows a reduction in
MMP-2 activity at 2 hour and 8 hour timepoints (Tukey’s multiple test, p < 0.02) (Fig.
8A). Activity of MMP-2 and MMP-9 was lowered with the administration of MMP
inhibitor compounds while the expression level of MMP-2 detected by western blot
analysis remained unaltered (Fig. 9) and the expression of MMP-9 increased at a 2 hour
timepoint (One-way ANOVA, Dunnett’s multiple comparison test, p < 0.02) and
decreased at an eight-hour timepoint (One-way ANOVA, Dunnett’s multiple comparison,
p <0.01) (Fig. 9).
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We also looked at gelatinase activity in mice treated with 19v and 19w MMP inhibitor
compounds. Gelatinase activity of MMP-2 increased at the 1 hour timepoint and then
activity level decreased at the later 1 hour timepoint when compared to the vehicleadministered control (Fig. 7B). Quantification of MMP-2 enzymatic activity (Fig. 8B)
detected with the cleavage of fluorogenic substrate did not show any statistical
significance at any timepoint, nor did the expression of MMP-9 change as detected by
western blot (Fig. 10C). Gelatinase activity of 19w compound showed little MMP-9
activity for all timepoints and high MMP-2 activity at the 30 minutes and later reduced at
the last 8 hour (Fig. 7C and 9C). Quantification of MMP-2 enzymatic activity assay
shows no statistical significance in activity between the timepoints to the nonadministered control (Fig. 8C). Western blot analysis shows unaltered expression of
MMP-2 (Fig. 10D) for all timepoints when compared to non-treated control. MMP-9
(Fig. 11D) expression is not statistically significant except for decrease in expression
between four-hour and eight-hour timepoint (One-way ANOVA, Tukey’s multiple
comparison test, p < 0.02).

Discussion:
No treatment is currently available to slow the progression of Huntington’s disease.
Many of the therapeutics available are to alleviate the symptoms resulting from the
disease. HD pathogenesis leads to neuronal death which is caused by toxic Htt fragments
formed by the proteolysis of mHtt (Mende-Mueller et al., 2001; Wellington et al., 2002b).
A previous study has shown that proteases other than calpains and caspases cleave mHtt,
specifically MMP-10 (Miller et al., 2010). Studies conducted in the field have detected
increase in MMP levels in the cerebrospinal fluid of HD patients as well as brain tissue of
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HD mice (Chang et al., 2015; Connolly et al., 2016). Our main aim was to investigate
MMPs as a therapeutic target for HD, in that by reducing or inhibiting MMPs we can
modulate the proteolysis of mHTT that can confer neuroprotection via the reduction of
the toxic N-terminal HTT fragments.
We can see a dysregulation of certain MMPs in our HD-patient derived NSC line when
compared to the CAG-corrected C116-NSC line. Previous research showed MMP-10
cleavage of N-terminal mHTT. However, all MMPs share sequence similarities; MMP-3
and MMP-10 are both classified as stromelysin (Table 1) and show an 86% similarity of
the catalytic domain (Bertini et al., 2004). MMP-3 has the ability to cleave mHtt, similar
to MMP-10 (unpublished data). To this end we compared the expression of MMP-3/10 in
our NSC line and found a significant increase (Fig. 1A) between the HD and control
corrected line as well as high nuclear localization in HD-NSCs compared to C116 (Fig.
1B). Furthermore, we also see a nuclear presence of HTT aggregate formation in
degenerating nucleus of the HD-NSCs (Fig. 2B), which leads us to speculate that MMP-3
and MMP-10 might interact with mHTT. It is unclear whether other members of the
MMP family contribute to cytotoxicity. This further provides the basis to investigate
MMP inhibition as a possible therapeutic target to combat cellular toxicity caused by
mHtt proteolysis.
We found that the expression of MMP-14 is lower in HD-NSCs compared to C116 (Fig.
2), which contradicts previous findings that showed an increase in MMP-14 levels in HD
mouse striatal cell line (Miller et al., 2010). These differences can be attributed to gene
expression variation between mouse and human cell lines. Differences can also result
from one being a fully differentiated striatal cell line and a multipotent NSC line.
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However, upregulation of MMP-14 have been reported in brain regions with high
amyloid pathology of AD patients as well as elevated MMP-14 levels near reactive
astrocytes containing degraded Aβ deposits (Liao & Van Nostrand, 2010). We can
speculate that the up-regulation of MMP-14 seen in the AD model to take a protective
role in clearing Aβ aggregates. This MMP-14 up-regulation model may have the same
role in clearing mHtt aggregates in HD, which is observed to be elevated in the
differentiated striatal cell that is less prone to stress compared to the pluripotent NSC
line. To validate possible increase in MMP-14 and mHTT clearance ability we need to
further differentiate our HD-NSCs into striatal cells and measure the levels of MMP-14
as well as the levels of mHTT fragments.
We also observed decreased levels of activated MMP-2 and increased levels of activated
MMP-9 in both the cellular lysates (Fig. 3A) and the conditioned media (Fig. 3B) of HDNSCs. Activation of MMP-2 requires forming a tetrameric proMMP-2 activation
complex involving MMP-14, TIMP-2 and MMP-2 (Li et al., 2017; Nagase, Visse, &
Murphy, 2006). Decreased expression of MMP-14 (Fig. 2), and TIMP-2 (Fig. 4B) in HDNSCs provides basis for the reduced activation of MMP-2 (Fig. 3A-B) seen by the
gelatin zymography. Immunocytochemistry analysis showed an increase in nuclear
expression of both MMP-2 and MMP-9 in degenerating nuclei (Fig. 3C). Many cellular
processes have been associated with MMP-2 and MMP-9 regulation. Nuclear expression
of MMP-2 has been associated with initiation of the apoptotic pathway through the
inactivation of poly-ADP-ribose-polymerase-1(PARP-1) (Kwan et al., 2004). Increase in
nuclear expression of MMP-2 and MMP-9 in degenerating nuclei correlates to initiation
of the apoptotic pathway in highly stressed NSCs. Determining the role of MMP-9 in
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neurodegenerative disease has been confounding in that MMP-9 has shown to be
neuroprotective in AD due to its ability to degrade Aβ (Mizoguchi et al., 2009) and
knockout of MMP-9 was shown to correlate with an increase in number of functional
dopaminergic neurons in models of PD (Annese et al., 2015). Over all, the consensus on
the significance of MMP-9 in neurodegenerative disease is that the increased expression
in cerebrospinal fluid is a potential biomarker and possibly a therapeutic target for
neurodegenerative disease, such as AD, PD, and HD (Vafadari, Salamian, & Kaczmarek,
2016).
Western blot analysis shows a decrease in TIMP-1 and TIMP-2 expression in HD-NSCs
compared to C116-NSCs (Fig. 4A-B). TIMPs are endogenous inhibitors of MMPs and
altered MMP:TIMP ratios have been investigated in neurodegenerative diseases where
elevated levels of TIMPs in CSF have been found in AD, PD, HD and ALS patients
(Lorenzl et al., 2003). TIMP-1 may function to protect against the MMP-mediated
expansion of neuroinflammatory markers induced by MMP-9 (Crocker, Pagenstecher, &
Campbell, 2004). Immunocytochemistry analysis further confirms the lower levels of
TIMP-1 expression in HD-NSCs (Fig. 4C). We also see co-localization of TIMP-1 and
mHtt in aggregate structure surrounding HD-NSCs. This leads us to speculate that TIMP1 inhibits MMP-10, which has been previous shown to cleave mHTT (Miller et al.,
2010). The dysregulation presented by an increase in MMP-10 expression and a decrease
in TIMP-1 expression proves that HD-NSCs are prone to more stress due to the inability
of TIMP-1 to regulate MMP-10 proteolysis which leads to mHTT fragment
accumulation. This leads us to consider that pharmacological inhibition of MMPs is a
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viable therapeutic strategy to reduce the cytotoxicity induced by mHTT fragment
accumulation.
MMP inhibitor compounds have been evaluated in various peripheral diseases, however
phase III clinical trials have been highly unsuccessful, due to the difficulty of formulating
a MMP inhibitor compound that can specifically target one family member, as MMP
family members are highly conserved in their protein structure (Bertini et al., 2004).
Becker et. al. group formulated a few compounds that specifically inhibited MMP-2,
MMP-9 and MMP-13 while sparing MMP-1 and membrane-bound MMP-14 through
hydroxamate-based inhibition. Hydroxamate-based inhibitors bind to the Zn2+ and distort
the geometry around the Zn2+ ion, reducing the enzyme’s Zn2+ binding ability
(Vandenbroucke & Libert, 2014b). Metalloproteinase selectivity was achieved by
exploiting the size difference of the S1’ subunit which created a steric blockade of the
binding site (Becker et al., 2010). MMP inhibition was conducted in blood plasma of rats
and the activity of MMP-2 and MMP-9 at IC50 value was < 0.1 and the bioavailability
was > 20% for each compound (Table 2).
We initially tested these three inhibitor compounds in HD mouse striatal cell lines and
found them to be neuroprotective. Previous research showed that wild type HTT protein
protects cells from apoptosis upstream of caspase-3 (Rigamonti et al., 2000), while
huntingtin with expanded polyglutamine undergoes cell death (Conforti et al., 2013). Our
caspase-3/7 enzymatic assay measured the levels of fluorogenic substrate cleaved by
activated the caspase-3/7 thus providing evidence of cells undergoing cell death. All three
MMP inhibitor compounds were found to be neuroprotective in that treated HD cells had
lowered caspase-3/7 activity compared to no difference in wild type mouse striatal cells
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(Fig. 5). As these compounds were neuroprotective in mouse striatal cells, we evaluated
these compounds in mice.
The compounds were selected based on properties that would predict they might cross the
BBB. However, whether this was the case required a careful analysis of PK in mice. We
evaluated these three compounds in C57/BL6 mice via a pharmacokinetic study coupled
to LC/MS. 19w compound were detected at higher amounts in both the plasma and brain
tissue at 30 minute timepoint compared to 19v and 9j. The amounts of MMP inhibitor
compounds decreased in respective to time, but only 9j compound showed a close
convergence of the plasma concentration curve and brain tissue concentration curve (Fig.
6A). The amount of inhibitor compound detected in the brain tissue was less than five
percent of the compound concentration detected in the blood plasma at each of the
timepoint. Comparison of the percent compound concentration (amount of compound in
brain relative to plasma levels) between each of the MMP inhibitors did not show any
one compound to be better at penetrating the blood brain barrier at the first four
timepoints. However, a comparison of the compound retained in the brain tissue in
comparison to the levels in blood plasma at the last timepoint showed a significant
increase in 9j inhibitor compound compared 19v or 19w (Fig. 6D), this might be due to
its smaller molecular weight and low cLogP value, which is a measure of compounds
hydrophilicity (Table 2). 9j compound has a smaller molecular weight and a lower
partition coefficient then other two compounds, 19v and 19w, two characteristics that
would allow for good permeation of a compound. We tested the compounds in wild type
mice to measure the overall ability of these compounds to cross the BBB. While there
was a modest retention of MMPi compound in the wild type mice we believe that in R6/2

21

mice, where the BBB is highly compromised (Drouin-Ouellet et al., 2015), more MMP
inhibitor compound would be retained.
Next, we wanted to test the specificity of MMP-2 and MMP-9 of each inhibitor
compound via gelatin zymography and enzymatic assay with fluorescent substrate. No
activity of MMP-2 was visually visible in the gelatin zymograms at the last timepoint of
9j, 19v, and 19w administered mice (Fig. 7A-C and Fig. 9) when compared to 30
minutes post injection which visually confirms the specificity of MMP inhibition on
MMP-2. MMP-2 specific enzymatic assay preformed on 19v (Fig. 8B) and 19w (Fig.
8C) showed no statistical significant in the reduction of MMP-2 enzymatic activity when
compared to non-treated mice. We did see a difference in MMP-2 activity at 2 hour and 8
hour time points in 9j administered (Fig. 8A) brain lysates which was visually displayed
by gelatin zymograms (Fig. 9) at the corresponding time point. We did not see any
altered protein expression of MMP-2 (Fig. 10B-C) and MMP-9 (Fig. 11B-C) as
quantified by western blot analysis for 19v and 19w. Interestingly for 9j administered
brain lysates no change in MMP-2 expression was noted (Fig. 10A), but a significant
difference in MMP-9 expression (Fig. 11A) at the corresponding time point (two and
eight-hour) when compared to non-MMP inhibitor treated mice. Increase in MMP-9
expression at the 2 hour timepoint might be due to a compensatory effect in the brain as a
result of MMP-2 inhibition as both MMP-2 and MMP-9 are in the same subclass of
MMP family member, gelatinases.
In conclusion, we found dysregulation of certain MMP family member in our patient
derived HD-NSC model. This dysregulation likely leads to proteolysis of mHTT and to
neuronal cell death. Thus, inhibition of proteases that cleave mHTT may be
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neuroprotective. MMP inhibitor compounds tested in mouse striatal cells were shown to
be neuroprotective as measured by caspase-3/7 activity. Our pharmacokinetic study of
MMP inhibitor compounds showed that 9j had a better retention in brain tissue at the end
time point compared to 19v and 19w. MMP inhibitor 9j also showed good specificity
towards inhibiting MMP-2. We would like to start a treatment with the 9j MMP inhibitor
compound to evaluate the benefit of MMP inhibition on locomotor decline in R6/2 mice.
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Tables and Figures:

Table 1: Structure and Classification of MMPs and TIMPs
Courtesy of Frontiers in Neuroscience journal originally appeared in (Naphade, Embusch,
Madushani, Ring, & Ellerby, 2018)
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Table 2: Structure and PK Parameters of MMP Inhibitor Compounds
Chemical structure of the MMP inhibitor compounds; 9v, 19v, and 19w. PK parameter’s
and MMP activity at IC50 values are courtesy of Journal of Medicinal Chemistry. Table
has been adapted from (Becker et al., 2010)
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Figure 1: Increased Expression of MMP-3/10 in HD-NSCs
(A) Western Blot analysis of MMP-3/10 shows increase in expression in HDNSCs and quantification when compared to α-tubulin shows a significant
increase evaluated by student t-test (n = 3 biological replicates, **p < 0.01).
(B) Immunofluorescence analysis shows increase in MMP-3/10 in HD-NSCs
compared to C116-NSCs. Increased presence of MMP-3/10 in apoptotic cells
as shown by white arrows. (scale bar: 20X = 100µm and 40X = 50µm).
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Originally appeared in (Naphade et al., 2018).

Figure 2: Decreased Expression of MMP-14 in HD-NSCs
(A) Western blot analysis of MMP-14 expression in HD-NSCs. Quantification of
MMP-14 expression compared to α-tubulin shows a significance (*p < 0.05)
reduction in MMP-14 expression in HD-NSCs.
(B) Immunocytochemistry analysis shows decreased expression in HD-NSCs and
higher expression of HTT expression. MMP-14 expression in HD-NSCs is
predominantly nuclear compared to C116-NSCs where HTT expression is also
observed in the cytoplasm. (Scale bar 20X = 100µm: 40X = 50µm) Originally
appeared in (Naphade et al., 2018).
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Figure 3: Altered MMP-2 and MMP-9 Activity and Localization in HDNSCs
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(A) Gelatin zymography shows decreased activity of MMP-2 and higher activity of
MMP-9 in cell lysates of HD-NSCs compared to C116-NSCs.
(B) Gelatin Zymography shows the same decreased activity of MMP-2 and increase
in activity of MMP-9 in conditioned media of HD-NSCs compared to C116NSCs.
(C) Immunocytochemistry show increase in MMP-2 expression in C116-NSCs and an
increased expression of MMP-2 of degenerating nuclei in both HD-NSCs and
C116-NSCs indicated by the white arrows. (scale bar: 20X = 100µm)
(D) Immunocytochemistry analysis of MMP-9 in HD-NSCs shows an increased
nuclear expression in HD-NSCs compared to C116-NSCs. (scale bar: 20X =
100µm). Originally appeared in (Naphade et al., 2018).
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Figure 4: TIMP-1 Expression in HD-NSCs
(A) TIMP-1 expression in HD-NSCs are lowered in HD-NSCs compared to C116NSCs. **p < 0.0.
(B) TIMP-2 expression in HD-NSCs are lowered in HD-NSCS compared to C116NSCs. *p < 0.05.
(C) Immunocytochemistry analysis shows an increase in TIMP-1 expression near
degenerating nuclei. (scale bar: 20X = 100µm). Originally appeared in (Naphade
et al., 2018).
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Figure 5: 9j, 19v, 19w are Neuroprotective in Mouse Striatal Cells
(A) Quantification of caspase-3/7 relative activity measured between wild type
(Hdh7Q/7Q) and HD (Hdh111Q/111Q) mouse striatal cells when treated with 10µm of
MMP inhibitor compound: 9j. No significant change in normal striatal cells, ***p
< 0.001 detected in CAG expanded striatal cells. Statistical analysis performed by
student t-test. Error bar = SD
(B) Quantification of caspase-3/7 relative activity measured between wild type
(Hdh7Q/7Q) and HD (Hdh 111Q/111Q) mouse striatal cells when treated with 10 µm of
MMP inhibitor compound: 19v. No significant change in normal striatal cells,
***p < 0.001 detected in CAG expanded striatal cells. Statistical analysis
performed by student t-test.
(C) Quantification of caspase-3/7 relative activity measured between wild type
(Hdh7Q/7Q) and HD (Hdh111Q/111Q) mouse striatal cells when treated with 10µm of
MMP inhibitor compound: 19w. No significant change in normal striatal cells,
**p < 0.01 detected in CAG expanded striatal cells. Statistical analysis performed
by student t-test.
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Figure 6: Pharmacokinetic Profile of MMP Inhibitor Compounds: 9j, 19v,
and 19w
(A) Plasma and brain levels of 9j compound in C57/BL6 mice after a single IP
administration (25mg/kg). Levels were detected at 0.5, 1, 2, 4, and 8 hours post
dosing. n = 3 mice/timepoint, error bars = S.D.
(B) Plasma and brain levels of 19v compound in C57/BL6 mice after a single IP
administration (25mg/kg). Levels were detected at 0.5, 1, 2, 4, and 8 hours post
dosing. n = 3 mice/timepoint, error bars = S.D.
(C) Plasma and brain levels of 19w compound in C57/BL6 mice after a single IP
administration (25mg/kg). Levels were detected at 0.5, 1, 2, 4, and 8 hours post
dosing. n = 3 mice/timepoint, error bars = S.D.
(D) Inhibitor compound retained in brain tissue compared to amount in plasma levels
at each timepoint (0.5, 1, 2, 4, and 8 hour post administration). n = 3/timepoint.
Statistical analysis performed by 2-way ANOVA, Tukey’s multiple test, P value:
*p < 0.05, ****p < 0.000l. Error bars = S.D.
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Figure 7: Visualization of MMP-2 and MMP-9 Activity by Gelatin
Zymography
(A) MMP-2 and MMP-9 activity in brain tissue at 0.5 and 4 hours post single
administration of 9j compound. Visually depicts a vast decrease in MMP-2 and
MMP-9 activity at later timepoint. n = 3 mice/timepoint.
(B) MMP-2 and MMP-9 activity in brain tissue at 0.5 and 4 hours post single
administration of 19v compound. Visually depicts a vast decrease in MMP-2
activity at later timepoint. n = 3 mice/timepoint.
(C) MMP-2 and MMP-9 activity in brain tissue at 0.5 and 4 hours post single
administration of 19w compound. Visually depicts a vast decrease in MMP-2
activity at later timepoint. n = 3 mice/timepoint.
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Figure 8: Measurement of MMP-2 Activity by Enzymatic Assay of
Fluorogenic Substrate
(A) Enzymatic activity of MMP-2 in brain lysates of 9j administered mice at various
timepoints (0.5, 1, 2, 4, 8 hour) post single administration. Inhibition of MMP-2
was investigated by fluorescently quenched substrate (4µm). Enzymatic assay of
9j treated whole brain lysate was compared against 9j treated lysate with broad
spectrum MMP inhibitor, 10µM NNGH. Overall increase in MMP-2 activity at
each timepoint compared to non-9j administered control. (n = 3mice/timepoint
with 3 biological replicates for each mouse). Statistical analysis by ordinary oneway ANOVA, Tukey’s multiple test: *p < 0.02. Error bar = SD.
(B) Enzymatic activity of MMP-2 in brain lysates of 19v administered mice at various
timepoints (0.5, 1, 2, 4, 8 hour) post administration. No statistical significance.
(C) Enzymatic activity of MMP-2 in brain lysates of 19w administered mice at
various timepoints (0.5, 1, 2, 4, 8 hour) post administration. No statistical
significance.
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Figure 9: Gelatin Zymogram of MMP Inhibitor Administered Mice
(A) Gelatin zymogram for 9j administered C57BL/6 mice at 0.5, 1, 2, and 4 hour
timepoint representing gelatinase, MMP-2 and MMP-9, activity. n = 3 animals
per timepoint, and 3 biological replicates.
(B) Gelatin zymogram for 9v administered C57BL/6 mice at 0.5, 1, 2, 4, and 8 hour
timepoint representing gelatinase, MMP-2 and MMP-9, activity. n = 3 animals
per timepoint, and 3 biological replicates.
(C) Gelatin zymogram for 19w administered C57BL/6 mice at 0.5, 1, 2, 4, and 8 hour
timepoint representing gelatinase, MMP-2 and MMP-9, activity. n = 3 animals
per timepoint, and 3 biological replicates.
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Figure 10: MMP-2 Expression of MMP Inhibitor Administered Mice
(A) Western blot of MMP-2 expression on whole brain lysates of mice administered
MMP inhibitor compound (9j, 19v, and 19w) at set timepoint (0.5, 1, 2, 4, and 8
hours) n = 3 per timepoint.
(B) Quantification of MMP-2 expression on whole brain lysates of 9j administered
mice at corresponding timepoint. Statistical analysis conducted by GraphPad
prism using ANOVA, Tukey’s multiple test. Error bar = SD.
(C) Quantification of MMP-2 expression on whole brain lysates of 19v administered
mice at corresponding timepoint. Statistical analysis conducted by GraphPad
prism using ANOVA, Tukey’s multiple test. Error bar = SD.
(D) Quantification of MMP-2 expression on whole brain lysates of 19w administered
mice at corresponding timepoint. Statistical analysis conducted by GraphPad
prism using ANOVA, Tukey’s multiple test. Error bar = SD.
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Figure 11: MMP-9 Expression in MMP Inhibitor Administered Mice
(A) Western blot of MMP-9 expression on whole brain lysates of mice administered
MMP inhibitor compound (9j, 19v, and 19w) at set timepoint (0.5, 1, 2, 4, and 8
hours) n = 3 per timepoint.
(B) Quantification of MMP-9 expression on whole brain lysates of 9j administered
mice at corresponding timepoint. Statistical analysis conducted by GraphPad
prism using ANOVA, Tukey’s multiple test. Error bar = SD.
(C) Quantification of MMP-9 expression on whole brain lysates of 19v administered
mice at corresponding timepoint. Statistical analysis conducted by GraphPad
prism using ANOVA, Tukey’s multiple test, P value: *p < 0.05. Error bar = SD.
(D) Quantification of MMP-9 expression on whole brain lysates of 19w administered
mice at corresponding timepoint. Statistical analysis conducted by GraphPad
prism using ANOVA, Tukey’s multiple test. Error bar = SD.
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Chapter 2
Abstract:
Huntington’s disease is an incurable genetic disorder with no current therapies. The
genetic underpinning of HD is caused by a CAG expansion in exon 1 of huntingtin gene
that encodes for HTT. One of the molecular pathologies of HD arises from the
neurotoxicity induced by processing of mutant huntingtin into N-terminal fragments.
Previous research has shown altered kinase signaling pathways to contribute to altered
localization of mutant huntingtin to the nucleus and possibly disrupting the
transcriptional regulation. Various protein kinase C activator compounds have been
evaluated in cancers as well as Alzheimer’s disease. Bryostain-1, a potent PKC activator,
have done well in phase II trials and have shown to improve cognition in Alzhiemer’s
patients. Bryostain-1 has not been evaluated in Huntington’s disease and we hypothesize
that PKC activation may have beneficial effects in Huntington’s Disease. To determine if
Byrostatin-1 has therapeutic benefit in HD, we conducted a preclinical trail in HD R6/2
mice. We measured weight, locomotion; rotarod, open field, clasping, and lifespan. R6/2
mice treated with Bryostain-1 did not show a significant improvement in locomotor
ability measured by rotarod performance or measures in open field testing. However, we
did find a significant increase in the average life span of Bryostain-1 HD R6/2 mice
compared to vehicle treated mice. We conclude while Bryostain-1 may not benefit the
deficit in locomotor ability, there is a beneficial outcome of increasing lifespan of R6/2
mice. We speculate that PKC activation may impact the regulation of seizure activity
leading to an increase in lifespan. However, more experiments need to be conducted to
further test this premise.
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Introduction:
HD is an autosomal dominant disease that effects 1 in 10,000 people. Huntington’s
Disease Collaborative Research group identified the genetic cause is due to a
polyglutamine expansion in the N-terminal region of the HTT protein (1993). Huntingtin
gene, overall, is highly conserved from flies to mammals, however exon 1 is the least
conserved region (Saudou & Humbert, 2016). The N-terminal portion of mutant
huntingtin protein is susceptible to proteolytic cleavage by caspases, calpains and MMP10, resulting in mutant N-terminal HTT cleavage fragments which have been found in
post mortem brain tissue of HD patients (Mende-Mueller et al., 2001; Miller et al., 2010;
Wellington et al., 2002b). Post translational modifications of huntingtin have also been
shown to modulate toxicity of mHTT (Cong et al., 2011; Huang et al., 2016; Schilling et
al., 2006b). For example acetylation mediates mHTT clearance and phosphorylation
decreases cleavage by caspase-3 and calpains (Jeong et al., 2009; Luo, Vacher, Davies, &
Rubinsztein, 2005; Saudou & Humbert, 2016). Kinase signaling has been shown to
regulate the subcellular localization of huntingtin protein in mouse striatal cells (Bowles,
Brooks, Dunnett, & Jones, 2015). The role of huntingtin protein in cellular processes is
vast and is not fully understood. A recent review speculates that with the many
interacting partners, HTT may serve as a scaffold protein by bringing multiple molecular
partners to coordinate cellular processes modulated by phosphorylation events (Saudou &
Humbert, 2016).
No current therapies exist to slow the progression of HD, thus one therapeutic avenue is
to identify kinase inhibitors or activators as therapeutic targets for HD. Diacylglycerol
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kinase ε (DGKε) was found in a library screen of inhibitor kinases that blocked mHtt
cellular toxicity in a HD mouse (HdhQ111/Q111) striatal cell line (Zhang et al., 2012).
Diacylglycerol kinases are enzymes that converts diacylglycerol (DAG) into phosphatidic
acid (PA) utilizing ATP, however when DAG is not converted to PA, it is an activator of
protein kinase C (PKC) (Sakane, Mizuno, Takahashi, & Sakai, 2018). Thus, the reduction
of cytotoxicity in striatal cells by the inhibition of DGKε might be due to the activation
protein kinase C.
PKC isozymes are family of kinases that phosphorylate large number of substrates and
regulate cellular processes, such as, cell proliferation, cell death, gene transcription and
translation. Thus, involvement of PKC activation has been seen in various human
diseases (Mochly-Rosen, Das, & Grimes, 2012). Two subgroups of PKCs, conventional
and novel isoforms, are activated by DAG as well as phorbol esters, such as TPA.
Impaired degradation of PKCα isoforms have been observed in cellular models of HD
and is speculated to be a cause of mHTT aggregates sequestration (Zemskov & Nukina,
2003). mRNA levels of PKCβII have been shown to be reduced in R6/2 mice compared
to wild type mice (Harris, Denovan-Wright, Hamilton, & Robertson, 2001). Even though
there is evidence of altered levels of PKC isoforms in HD, the role of PKC activators and
PKC signaling have not be fully characterized.
PKC activators have been investigated as therapeutics for many diseases by formulating
compounds that target the binding of the C1 regulator domain and mimics the DGbinding, one of which is Bryostatin-1. Bryostain-1 is a potent activator of PKCε and in a
Phase II clinical trial for the treatment of Alzheimer’s Disease. Bryostain-1 has been
shown to increase the mini-mental state examination (Nelson et al., 2017) To test if PKC
40

activation is neuroprotective in HD cell models, we evaluated three known PKC
activators- Prostratin, Farnesyl thiotriazole and Bryostatin-1. We found that Prostratin
and Farnesyl thiotriazole were neuroprotective in our striatal HD mouse cells. Initially,
we tested Prostratin in R6/2 mice and found it extended the lifespan of these mice by 20
days (data not shown). However, Prostratin has been shown to be toxic in Phase III
clinical trials for AIDs. Therefore, we tested Bryostatin-1’s potential as a therapeutic for
HD. We evaluated Bryostatin-1 in HD R6/2 mouse model measuring rotarod, open field,
weight and lifespan. We used the well characterized R6/2 HD mouse model as it has
reproducible HD like phenotypes and a short lifespan (12-15 weeks) (Carter et al., 1999)

Methods:
Drug Dosage Treatment
Bryostain-1 was administered intravenously and intraperitoneally in varying
concentrations into wild type and R6/2 three-month old mice. Intravenous concentrations
were delivered at 6.25 µg/kg, 12.5 µg/kg, and 15 µg/kg, intraperitoneal concentrations
were 30 µg/kg, 40 µg/kg and 50 µg/kg. Then each mouse, n = 2 for each concentration,
was euthanized at one hour post injection and its brain harvested for western blot
analysis.
Bryostatin-1 was purchased from Sigma Aldrich. R6/2 mice (Jackson Labs) were
administered injections of 40 mg/kg Bryostain-1 three times per week. Bryostain-1 was
resuspended in 10% DMSO in saline and made fresh every day. Treatment of Bryostain-1
started at week six and continued until death. Weights of mice were measured each week.
The mice were grouped as follows: n = 15 no-treatment, and n = 15 treated.
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Caspase-3/7 Assay
In vitro assessment of cytotoxicity was measured in HdH111Q/111Q mouse striatal cells as
well as HD-NSCs of Bryostain-1 treated cells in serum starved media. Methods for the
caspase-3/7 assay are identical to that found in Chapter 1. Statistical analysis by twotailed student t-test conducted by GraphPad prism, with 6 biological replicates.
Western Blot
Bryostatin-1 treated mice were sacrificed at one hour post injection. The brains were
harvested, and the left half of the brain was homogenized in 800ul of lysis buffer (10 ml
TPER, 1 tablet EDTA-free protein inhibitor, DNAse1, 1.2 mM MgCl2, 1µm
expoxomycin, 100 µl phosphatase inhibitor cocktail II, 50µ MTSA, 30 nM Nicotinamide,
30 µM Sodium butyrate) and sonicated 3X for 30 seconds at 40% amplitude. Samples
then were centrifuged at 14,000 rpm at 4°C and the supernatant collected for western blot
analysis. Protein concentrations were measured using BCA assay (Pierce). 40 µg of total
protein lysate was added to 4X LDS sample buffer (Invitrogen) and 1µl of 1M DTT and
boiled for 10 minutes at 95°C. SDS-PAGE was performed on 4% – 12% NuPAge BisTris gel (Invitrogen). Gels were run at constant 200V for 55 minutes in MES (Invitrogen)
running buffer then transferred to PVDF membrane in 1X NuPage transfer buffer and run
at 20V in 4ºC overnight. Membranes were then blocked in TBS with 0.1% Tween 20
(TBS-T) and 5 % non-fat milk for one hour. Primary antibody was reconstituted in 5%
BSA in 1X TBS-T and then was probed overnight at 4°C, followed by incubation with
secondary antibody for 3 hours at room temperature. Lastly the membranes were washed
(3X) for 10 minutes and were developed using Pierce ECL (Thermo Scientific) and band
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intensity was quantified by ImageQuant. Primary antibody used: Phosphorylated PKC
substrate (1:1000).

Rotarod
Behavioral data collection was performed in a blind study matter. Motor performance
was assessed using rotarod analysis. Initial rotarod testing was conducted prior to drug
treatment and mice were randomized by their initial performance and weight into
separate treatment cohorts. Rotarod assessment was conducted over three consecutive
days during the light cycle at week 7, 9, 11, 13, 15, and 17. Each day consisted of a
training session at constant (4 rpm) for five-minutes followed by three trial runs at
accelerating speed (4 - 44 rpm) for total of 6 minutes. Statistical analysis was conducted
on the third consecutive day using one-way ANOVA by GraphPad Prism software.
Open Field
Behavioral data collection was performed in a blind study matter and locomotor
performance was assessed by open field. Open field assessment was conduct during the
dark cycle at week 9, 12, and 15. Mice were placed in field boxes and TruScan system
measured parameters in the vertical and floor plane. Recording was taken for total of ten
minutes at one-minute time intervals. Analysis was conducted on the total run time of ten
minutes and parameters were compared between treated and non-treated cohorts.
Statistical analysis was conducted by GraphPad Prism with one-way ANOVA.
Hind Limb Clasping
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Hind limb scoring was assessed in treated and non-treated groups at the end of each
week. During tail suspension, normal mice will struggle as observed by flailing limb
movement. Mice with neurological problems will maintain their limbs fully pressed
against the body, termed clasping. Mice were lifted from the base of their tails and held
straight down for ten seconds, observations were recorded, and a score was given as
described below for hind limb clasping. Three readings were recorded, and the last score
was taken for analysis. Scoring scale: 0 = no clasping of either hind limb for 10 second
period, 1 = clasping of one hind limb, 2 = clasping of both hind limbs, 3 = both hind
limbs fully clasped from initial tail suspension. Statistical analysis performed by
GraphPad prism using one-way ANOVA.

Results:
We measured cytotoxicity levels of non-tumor promoting activators of PKC in serum
deprived mouse HD striatal cells (Hdh111Q/111Q) and HD-NSCs (Fig. 12). We found that
Prostratin (n = 6 biological replicates) at 2µM (p < 0.001) and Farnesyl thiotriazole at
25µM (p < 0.001) significantly reduce levels of caspase-3/7 activity. However,
Bryostatin-1 was not neuroprotective at the concentrations tested (Fig. 12A). Next, we
evaluated the caspase-3/7 activity in serum deprived HD-NSCs treated with Bryostatin-1
(n = 6 biological replicates) at varying concentrations and no statistical significance was
found (Fig. 12B). Statistical analysis was conducted by ANOVA utilizing GraphPad
prism.
Initially, we conducted a preclinical trial of R6/2 mice with Prostratin based on its
neuroprotective effect on the immortalized mouse HD striatal cells. We found that
Prostratin resulted in an increased lifespan of the R6/2 mice suggesting it provided some
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benefits to the HD mice. However, Prostratin has been reported in Phase II clinical trials
in AIDs patients to have toxicity. The related drug Byrostatin-1 is in Phase III trials for
AD and is safe. Therefore, we evaluated Bryostatin-1 in HD R6/2 mice. First, we
performed a dose response in wild type and R6/2 mice via IP and intravenous (IV) routes
of administration to determine toxicity and levels of PKC activation. We administered 30
µg, 40 µg, and 50 µg intraperitoneally (n = 2 mice per concentration) and sacrificed mice
after one hour post injection and collected the brains for western blot analysis to detect
phosphorylated PKC substrates. We did the same dosage response via tail vein injection
at 6.65 µg, 12.5 µg, 25 µg, 50 µg, and 100 µg concentrations and visualized
phosphorylated PKC substrate. Western blot analysis revealed a significant increase in
phosphorylated PKC substrates at 30, 40, and 50µg of Bryostatin-1 administration using
IP injections one-hour post injection in the brain (Fig. 13A). A similar increase in
phosphorylated PKC substrates was detected at 50µg and 100µg of Bryostatin-1
administration using IV injection (Fig. 13B). Lower amounts of Bryostatin-1
administration using IV injection did not result in the phosphorylation of PKC substrates
Based on dose response with Bryostatin, we treated HD R6/2 (n =15 per group),
aggressive HD mouse model, with 20 µg of Bryostatin-1 (in 10% DMSO) using X
injection three times a week starting at six weeks of age. Subsequently, we monitored and
weighed the mice every week as well as assessed hind limb clasping ability. We also
conducted locomotor assessment with rotarod every two weeks and open field testing
every three weeks until death. Bryostain-1 treated mice did on average live 20% longer
than the non-treated group (Fig. 14A). Although the R6/2 mice loss weight as the disease
progresses we did not detect a statistical difference between Bryostatin-1 and vehicle
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treated mice (Fig. 14B). Further evaluation of the R6/2 mice treated with Bryostatin-1
and vehicle did not yield any statistical difference in rotarod (Fig. 14C) although there
may be a slight non-statistical improvement. Evaluation of multiple parameters measured
by open field assessment in R6/2 mice treated with Bryostatin-1 and vehicle (Fig. 15)
were negative. We did not detect any change in hind limb collapse scoring with
Bryostatin-1 treatment (Fig. 14D).

Discussion:
Bryostain-1 has been evaluated in mice and patients as a possible therapeutic for
Alzheimer ’s disease (AD). Treatment with Bryostatin has been shown to prevent
synaptic loss and improve cognitive function (Alkon, Epstein, Kuzirian, Bennett, &
Nelson, 2005; Nelson et al., 2017). Our study evaluated the effects of Bryostatin-1 of
cytotoxicity in HD cell lines and behavioral effects in aggressive model of HD mice.
Bryostatin-1 treatment in the HD mouse striatal cell line didn’t show a significant
neuroprotective effect, compared to Prostrain and Farnesyl thiotriazole, nor was the drug
found to be protective in human NSCs.
There are various PKC isoforms, novel (δ, ε, η, and θ) and conventional (α, βII, and γ)
that are regulated by various subgroups of DGK’s that regulate various cellular processes
in tissue specific and cell specific manner (Sakane et al., 2018). Type 1 DGKα have been
reported to be involved with T-cell anergy induction, cell motility, cell growth and
apoptosis, and immune response, while DGKε have been reported to regulate seizure
activity and long term potentials (Sakane et al., 2018; Singh et al., 2017). Thus,
Bryostatin-1, a PKC activator drug, also has a selectivity towards the activation of certain
PCK isoforms and have been known to have a 2-fold selectivity for PKCε over PKCα,
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and δ (Mochly-Rosen et al., 2012). There have been studies that shows various ranges of
effect on the CNS. For example, studies of Bryostatin-1 in Alzheimer’s Phase IIA clinical
trials have shown that an increase in PKCε is associated with cognitive improvements
evaluated by mini-mental state examination (Nelson et al., 2017). Bryostatin-1 treatment
has been shown to alleviate multiple sclerosis (MS) in mouse models and in vitro
promoted anti-inflammatory phenotypes in various immune cells (Kornberg et al., 2018).
Confounding reports have also reported Bryostatin-1 to induce secretions of chemokines
and proinflammatory cytokines in AID-infected astrocytes and to disrupt the BBB for the
transmigration of neutrophils (Proust, Barat, Leboeuf, Drouin, & Tremblay, 2017).
Nevertheless, the BBB is highly compromised in the brain of HD mice, thus we can
speculate the increase in the recruitment of neutrophils via activation of PCKα to be
beneficial in clearing mHTT fragments.
Both AD and multiple sclerosis (MS) treatment models have shown different effects of
Bryostatin-1 in the targeted activation of various PCK isoforms and in different tissue
and cells of the central nervous system. To this end we can speculate that the PCK
isoform that is targeted by Bryostatin-1 is absent in our HD mouse striatal and human
NSC models and therefore is not affected by Bryostain-1 treatment. However, we did see
activation of phosphorylated PKC substrate in our Bryostain-1 treated wild-type and R6/2
mice suggesting a PKC family member is activated in vivo. While no statistical
significance in the survival curve of the treated and non-treated, Bryostain-1 treated mice
did live 20% longer. This may be due to difference in seizure activity between the treated
and non-treated groups during the latter stage of disease progression, as it has been
shown that PKCε to regulate seizure activity (Rodriguez de Turco, E B et al., 2001).
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Many of the R6/2 mice have seizures that induces death and we speculate this is reduced
with Bryostain-1treatment. We did not measure this quantitatively and therefore future
experiment comparing electroencephalogram (EEG) readings of Bryostatin-1 treated and
non-treated might provide information of any variation in electrical signaling that takes
place in the brain that may correlate to variation in seizure activity of the treated and nontreated mice. We also did not conduct studies on learning and memory in these mice and
Bryostatin-1 may also impact this in R6/2 mice.
In conclusion, we detected an increase in phosphorylated PCK substrates in the brain
lysates of mice administered Bryostain-1. We did not detect a neuroprotective effect of
Bryostatin-1 treatment in our HD mouse striatal cells or human NSCs which may be
related to dose or low levels of the target PKC family member. Our preclinical trial with
Bryostatin-1 in HD R6/2 mice suggests an increase in the mean survival rate of the mice.
We speculate this benefit of Bryostain-1 be through the regulation of seizure activity. We
did not detect improvements in weight or motor function. Further research needs to be
conducted to establish the PCK isoform, when activated, is neuroprotective and blocks
seizure activity.
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Tables and Figures:

Figure 12: Cytotoxicity Evaluated in Striatal Hdh111Q/111Q cells and HDNSCs
(A) Non-tumor promoting PKC activator, Prostratin (2 µm) and Farnesyl thiotriazole
(25 µm) treatment in HD mouse striatal cells in serum deprived media is
neuroprotective as measured by decrease in caspase-3/7 activity. student t-test,
****p < 0.001, n = 6 biological replicates (BR), error bar = SD.
(B) Bryostatin-1 treatment in HD-NSCs in serum deprived media show no statistical
significance in the reduction of caspase-3/7 activity. student t-test used for
statistical analysis, n = 6 BR, error bar = SD.
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Figure 13: Bryostatin-1 Dosage Response via IP and IV Route
(A) Bryostatin-1 administered IP at 0, 30 µg, 40 µg, and 50 µg (n = 2 for each dose).
Western blot analysis of R6/2 brains lysates detected phosphorylated PCK
substrates (49 kDa – 98 kDa) (P-(s) PKC substrate, 1:1000).
(B) Bryostatin-1 administered IV at 0, 6.6 µg, 12.5 µg (n = 3), 50 µg and 100 µg (n =
2 for each dose). Western blot analysis of R6/2 brains lysates detected
phosphorylated PCK substrates.
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Figure 14: Behavioral Study of Bryostatin-1 Treated R6/2 Mice
(A) Survival curve between control and Bryostain-1 treated group (n = 15). Bryostain1 treated mice lived on average 2 weeks longer. ANOVA statistical analysis
conducted by GraphPad prism. error bar =SD.
(B) Body weight of control and Bryostatin-1 treated group. No statistical significant
was measure, except at week 7 and 8, where the dosage of drug was lowered to 25
µg/kg. ANOVA statistical analysis conducted by GraphPad prism. error bar =SD.
(C) Assessment of locomotor ability of treated and non-treated mice does not show a
statistical significance in relation to an increase in age. ANOVA statistical
analysis conducted by GraphPad prism. error bar =SD.
(D) Hind limb clasping assay shows an increase in clasping of hind limbs due to age,
but no statistical significance seen between the treated and non-treated. ANOVA
statistical analysis conducted by GraphPad prism. error bar =SD.
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Figure 15: Open Field Testing of Bryostain-1 Treated R6/2 mice
(A) Open field testing assessment conducted at week 9, 12, and 15 between
Bryostatin-1 administered R6/2 cohorts and non-treated R6/2 mice. Parameters
measured are number of moves for total of 10 minutes. (B) Distance traveled in
10 minutes, (C) Total movement time in 10 minutes, (D) Average distance per
movement made, (E) number of entries made into vertical plane, (F) Total number
of vertical moves made, (G) Total distance made in the vertical plane, (H)
Amount of time spent in vertical plane. ANOVA statistical analysis conducted by
GraphPad prism, no statistical significance. Error bar = SD
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